Feb 05, 2024
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT), announced today that members of the management team will present at the following upcoming investor conferences: Guggenheim Healthcare Talks 6 th Annual Biotechnology Conference , the St.
Jan 30, 2024
- Company to focus exclusively on commercialization and development of Abecma , in partnership with Bristol Myers Squibb   - - Company to sell R&D pipeline to Regeneron to launch Regeneron Cell Medicines business led by 2seventy bio’s Chief Scientific Officer, Philip Gregory - Chip Baird named